Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety. They are reported to be useful for the treatment of cancer.
Sironax Ltd. has discovered (+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, diabetic neuropathy, multiple sclerosis, Parkinson's disease, chemotherapy-induced peripheral neuropathy and traumatic brain injury.
Haisco Pharmaceutical Group Co. Ltd. has identified phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of breast cancer.
Boehringer Ingelheim Pharma GmbH & Co KG has synthesized D-3-phosphoglycerate dehydrogenase (3-PGDH; PHGDH) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, infections and inflammation.
Ependymoma is a brain cancer that occurs during childhood and is usually resistant to cytotoxic therapy. Molecular profiling has helped in better understanding the mechanisms behind the disease and has unveiled EPH receptor B2 (EPHB2) as a critical player in driving disease.
The use of artificial intelligence (AI) in drug discovery has shown promise in recent years with a growing number of new compounds moving forward in the pipeline.
Rgenta Therapeutics Inc. has received IND clearance by the FDA for RGT-61159, which is being developed for adenoid cystic carcinoma, colorectal cancer and other solid tumors, as well as acute myeloid leukemia.
Ipsen SA and Foreseen Technology (Beijing) Co. Ltd. have entered into an exclusive global licensing agreement for FS-001, an antibody-drug conjugate (ADC) that targets a novel tumor-associated antigen highly expressed across a range of solid tumors that was identified through the application of Foreseen’s proprietary proteomic platforms.
Zhejiang University of Technology has reported preclinical safety data for the novel multitargeting compound XYY-CP1106, being developed for the treatment of Alzheimer’s disease (AD). XYY-CP1106 is a multitargeted anti-AD compound that has previously demonstrated strong monoamine oxidase B (MAO-B) inhibition (IC50=14.7 nM), high Fe3+ chelation (pFe3+=18.04), no in vitro cytotoxicity and protection against cellular oxidative damage.
RSS
